awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q36901517-5CD89DB9-63EE-4BBD-AFDB-9718A1B36CC8
Q36901517-5CD89DB9-63EE-4BBD-AFDB-9718A1B36CC8
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36901517-5CD89DB9-63EE-4BBD-AFDB-9718A1B36CC8
PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells
P2860
Q36901517-5CD89DB9-63EE-4BBD-AFDB-9718A1B36CC8
BestRank
Statement
http://www.wikidata.org/entity/statement/Q36901517-5CD89DB9-63EE-4BBD-AFDB-9718A1B36CC8
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
d7df6c9946f88bd1ecae8f349490ff496771a67c
P2860
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer